Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 17, 2017

View Archived Issues

Galderma initiates phase II trial of NP-000888 for plaque and nail psoriasis

Signum Biosciences awarded NIAID grant to develop candidate for atopic dermatitis

The University of Nantes presents new antifungal/antiparasitic agents.

Catalyst Therapeutics identifies new bromodomain inhibitors

Phase II trial investigates gene therapy CYL-02 for locally advanced pancreatic cancer

U.S. orphan designations granted to atezolizumab, atezolizumab plus cobimetinib for melanoma

G100 given FDA orphan drug designation for follicular lymphoma

Versant Ventures announces launch of Jecure Therapeutics

Spotlight Innovation enters second Zika agreement with Florida State University

FDA approves Spiriva Respimat for use in children

NIH Blueprint Neurotherapeutics Network awards grant to Knopp Biosciences

Tracon Pharmaceuticals begins dosing in phase III TAPPAS study of TRC-105

Amygdala Neurosciences acquires ALDH2 inhibitor from Gilead

Capricor terminates natriuretic peptide receptor agonist license agreement with Mayo Clinic

High virologic response rates seen with bictegravir regimen in phase II trial

Phase III study of Lynparza meets primary endpoint in BRCA-mutated metastatic breast cancer

Five-marker methylation panel detected for ulcerative colitis-associated neoplasia

XBiotech's phase II study of MABp1 meets primary endpoint

Chugai seeks Japanese approval for atezolizumab for NSCLC

FDA accepts Mylan and Biocon's BLA for MYL-1401H for review

Clinical results with velmanase alfa in adults and children reported

Astellas Pharma describes novel MC4 receptor agonists

Allergan discloses new fMet-Leu-Phe/N-formyl peptide receptor 2 agonists

Phase I/II results of rAAV2/5-hNA-GLU in children with MPS IIIB presented

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...